AnaptysBio, Inc. (ANAB) earnings
ANAB earnings moved a median of -4.69% by the close. Quarterly and annual ANAB reports and results, each read against the price at its own news timestamp. Back to the ANAB overview →
20 measured ANAB earnings events.
Where these ANAB earnings landedvs 20 measured ANAB earnings reactions
| Middle 50% of ANAB earnings reactions | -8.77% to -2.50% |
|---|---|
| Median reaction (to close) | -4.69% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 ANAB earnings events with a measured close landed between -8.77% and -2.50%; 5% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update | Press release | -5.99% | -3.71% | |
| Form 10-Q ANAPTYSBIO, INC For: Mar 31 | SEC filing · Form 10-Q | -5.99% | -3.71% | |
| Form 10-K/A ANAPTYSBIO, INC For: Dec 31 | SEC filing · Form 10-K | -1.44% | -4.33% | |
| Form 10-K ANAPTYSBIO, INC For: Dec 31 | SEC filing · Form 10-K | -2.83% | +7.97% | |
| Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update | Press release | -6.04% | -8.21% | |
| Form 10-Q ANAPTYSBIO, INC For: Sep 30 | SEC filing · Form 10-Q | -6.04% | -8.21% | |
| Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update | Press release | -5.05% | -13.54% | |
| Form 10-Q ANAPTYSBIO, INC For: Jun 30 | SEC filing · Form 10-Q | -5.05% | -13.54% | |
| Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update | Press release | +0.47% | -5.09% | |
| Form 10-Q ANAPTYSBIO, INC For: Mar 31 | SEC filing · Form 10-Q | +0.47% | -5.09% | |
| Form 10-K ANAPTYSBIO, INC For: Dec 31 | SEC filing · Form 10-K | -12.52% | -13.52% | |
| Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update | Press release | -2.21% | +0.00% | |
| Form 10-Q ANAPTYSBIO, INC For: Sep 30 | SEC filing · Form 10-Q | -2.21% | +0.00% | |
| Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update | Press release | -1.84% | -4.69% | |
| Form 10-Q ANAPTYSBIO, INC For: Jun 30 | SEC filing · Form 10-Q | -1.84% | -4.69% | |
| Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update | Press release | -2.10% | -10.44% | |
| Form 10-Q ANAPTYSBIO, INC For: Mar 31 | SEC filing · Form 10-Q | -2.10% | -10.44% | |
| Form 10-K ANAPTYSBIO, INC For: Dec 31 | SEC filing · Form 10-K | -0.65% | -3.12% | |
| Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update | Press release | -0.28% | -0.62% | |
| Form 10-Q ANAPTYSBIO, INC For: Sep 30 | SEC filing · Form 10-Q | -0.28% | -0.62% |
Keep exploring
More ANAB: analyst actions → · SEC filings → · ANAB overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Avid Bioservices, Inc. (CDMO) | 354 | 0.00% | 49% |
| Celcuity Inc. (CELC) | 354 | +0.13% | 52% |
| REGENERX BIOPHARMS INC (RGRX) | 343 | 0.00% | 36% |
| Allena Pharmaceuticals, Inc. (ALNA) | 342 | 0.00% | 41% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.